Last $22.08 USD
Change Today +0.17 / 0.78%
Volume 17.5K
HPTX On Other Exchanges
As of 10:17 AM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

hyperion therapeutics inc (HPTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $32.98
52 Week Low
01/2/14 - $19.59
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hyperion therapeutics inc (HPTX) Related Bloomberg News

View More Bloomberg News

hyperion therapeutics inc (HPTX) Related Businessweek News

No Related Businessweek News Found

hyperion therapeutics inc (HPTX) Details

Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The company’s products include RAVICTI, which is used as a nitrogen-binding agent for chronic management of adult and pediatric urea cycle disorder (UCD) patients greater than two years of age, who cannot be managed by dietary protein restriction and/or amino acid supplementation alone; and BUPHENYL, an FDA-approved therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.

54 Employees
Last Reported Date: 03/7/14
Founded in 2006

hyperion therapeutics inc (HPTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $575.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $347.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $375.0K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $347.0K
Chief Legal & Compliance Officer, Senior Vice...
Total Annual Compensation: $195.9K
Compensation as of Fiscal Year 2013.

hyperion therapeutics inc (HPTX) Key Developments

Hyperion Therapeutics, Inc.(NasdaqGS:HPTX) added to NASDAQ Biotechnology Index

Hyperion Therapeutics, Inc. will be added to the NASDAQ Biotechnology Index.

Hyperion Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM

Hyperion Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:10 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Jeffrey S. Farrow, Chief Financial Officer, Principal Accounting Officer and Secretary.

Bruce F. Scharschmidt Intends to Step Down as Chief Medical and Development Officer of Hyperion Therapeutics, Inc

Hyperion Therapeutics, Inc. announced that Bruce F. Scharschmidt, intends to step down from his full time position as the Company's Chief Medical and Development Officer and will transition to the position of Emeritus Chief Medical Officer. Dr. Scharschmidt is expected to transition to his Emeritus role in the middle of next year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HPTX:US $22.08 USD +0.17

HPTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HPTX.
View Industry Companies

Industry Analysis


Industry Average

Valuation HPTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at